Skip to content Skip to footer
Biopharma M&A Top 20 2024

Top 20 Biopharma M&A of 2024 by Total Deal Value

Top 20 Biopharma M&A of 2024 by Total Deal ValueShots:Dealmaking in 2024 experienced fluctuations due to regulatory challenges and increasing pressure from the Inflation Reduction ActThe highest-value deal of the year was Vertex’s acquisition of Alpine Immune Sciences for $4.9B, followed by Gilead’s acquisition of CymaBay for $4.3B and Lilly’s acquisition of…

Read more

ThoughtSpot_Saurabh Chaubey2

Bridging the Biopharma Gap with Consulting Firms

Shots: In the extremely competitive biopharma industry, it’s never too soon to learn about the players who help biopharma companies understand the evolving landscape of the biopharma industry Consulting firms are instrumental in guiding biopharma companies in decision-making, understanding the regulatory challenges, and market dynamics This article from PharmaShots unfolds the benefits of onboarding a…

Read more